Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.
Type:
Application
Filed:
January 18, 2024
Publication date:
October 17, 2024
Inventors:
Carl H. June, Michael Milone, Yangbing Zhao, Lawrence G. Lum, Archana Thakur
Abstract: A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to ENTPD3, is provided.
Type:
Application
Filed:
January 23, 2024
Publication date:
October 17, 2024
Inventors:
Elmar JAECKEL, Matthias HARDTKE-WOLENSKI, Michael HUST, Tom PIEPER, Tobias RIET
Abstract: The present disclosure provides improved T cell receptors, polynucleotides, polypeptides, vectors, cells, and methods of using the same. Particularly, the present invention relates to T cell receptor-based constructs engineered to comprise one or more additional binding domains, and methods of using the same. In certain embodiments, the one or more binding domains are fused to one or both TCR variable domains. In particular embodiments, the one or more additional binding domains are linked to the TCR with one or more polypeptide linkers.
Abstract: The present disclosure relates generally to methods of treating or preventing cancer, the method comprising administering to a subject in need of treatment at least one tissue differentiation factor related polypeptide (TDFRP), wherein the TDFRP is administered in an amount effective to treat the cancer in the subject.
Type:
Application
Filed:
March 22, 2024
Publication date:
October 17, 2024
Inventors:
William Dean Carlson, Peter Keck, Dattatreyamurty Bosukonda, Frederic Roy Carlson, Jr.
Abstract: The present invention relates to an anti-inflammatory active composition comprising extracellular vesicles isolated from tonsil-derived mesenchymal stem cells. Specifically, the anti-inflammatory active composition comprising extracellular vesicles isolated from tonsil-derived mesenchymal stem cells of the present invention has an excellent activity of inhibiting TNF-?, which is an inflammatory cytokine, and an excellent activity of increasing IL-10, which is an anti-inflammatory cytokine, and thus it may be usefully applied to the prevention, suppression, alleviation, amelioration or treatment of inflammation.
Abstract: The present disclosure relates generally to neural progenitor cells and therapeutic uses thereof. More particularly, the present disclosure provides cervical spinal cord-specific neural progenitor cells (cerNPCs), methods of producing cerNPCs, pharmaceutical compositions comprising cerNPCs. and methods of treating neurological diseases or disorders with the cerNPCs.
Type:
Application
Filed:
August 3, 2022
Publication date:
October 17, 2024
Applicant:
University Health Network
Inventors:
Michael George FEHLINGS, Mohammad KHAZAEI, Christopher S. AHUJA
Abstract: The present invention is related to a method for treating and/or preventing Alzheimer's disease, especially using mitochondria for treatment and/or prevention of Alzheimer's disease.
Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods of making genetically modified cells comprising a synthetic circuit that is responsive to a circadian input to the cell and methods of use thereof. This disclosure uses a cells circadian rythym to provide gene-based delivery of biologic drugs at prescribed times, phases and frequencies. Once reprogrammed, the cells can be reimplanted in the body for this purpose.
Abstract: Described herein are methods and compositions related to treating cancer using cardiosphere derived cells (CDCs) and/or extracellular vesicles (EVs). In some embodiments, the EVs are heart-derived EVs (e.g., cardiosphere-derived exosomes, CDC-derived exosomes, cardiosphere-derived microvesicles, CDC-derived microvesicles, or combinations thereof). In some embodiments, methods of treating cancer in a subject are provided. In some embodiments, CDCs and/or EVs are administered to a subject to treat cancer. In some embodiments, the CDCs and/or EVs are provided in a pharmaceutical formulation.
Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
Type:
Application
Filed:
February 21, 2024
Publication date:
October 17, 2024
Applicant:
Regents of the University of Minnesota
Inventors:
Michael J. SADOWSKY, Alexander KHORUTS, Alexa R. WEINGARDEN, Matthew J. HAMILTON
Abstract: Provided are compositions comprising a bee-derived component and a marine plasma, and methods of preparation thereof, in particular wherein the bee-derived component comprises or is derived from zabrus. These compositions may be used in the treatment or prevention of disease, especially bacterial, viral, fungal, and/or parasitic diseases.
Abstract: The present disclosure relates to methods and compositions for oral delivery of nutrients and/or pharmaceuticals, particularly for tissue repair and regeneration of the body, and more particularly to methods and compositions for protecting the mucosal tissue from damages caused by irritants and for promoting repair and regeneration of damaged or dysfunctional mucosal tissue in the gastrointestinal tract, especially for the treatment of a gastrointestinal disorder such as Crohn's disease.
Abstract: Disclosed in the present invention is a combined formulation capable of ameliorating gastrointestinal adverse effects caused by oxaliplatin, which comprises lycium barbarum polysaccharides and Akkermansia muciniphila; the lycium barbarum polysaccharide is obtained by removing small molecular substances by ethanol extraction, then continuously performing reflux extraction by using water, and separating by using a hollow fiber ultrafiltration device; Akkermansia muciniphila is Akkermansia muciniphila ATCC BAA835; the combined formulation provided by the present invention can ameliorate intestinal injury, reduce inflammatory factors and maintain intestinal barriers, and thus can be used as a functional food or a medicine to ameliorate gastrointestinal adverse effects caused by oxaliplatin.
Type:
Application
Filed:
June 26, 2024
Publication date:
October 17, 2024
Applicant:
NANJING UNIVERSITY OF CHINESE MEDICINE
Inventors:
Jinao DUAN, Sheng GUO, Wanchen CUI, Haifeng LIU
Abstract: Disclosed herein are probiotic bacterial strains or species that produce short chain fatty acids (SCFA), such as butyrate, and compositions comprising the same. The bacterial strains or compositions prepared thereby are used in preparing food, supplements, compositions, and other consumables to provide health benefits, including therapeutic applications, for a variety of disorders, including metabolic, immune, intestinal, and inflammatory disorders. Thus, also disclosed herein are methods of treating a subject suffering from a disorder, such as a metabolic disorder, an immune disorder, an intestinal disorder, or an inflammatory disorder with a composition comprising the probiotic bacterial strains or species disclosed herein. Uses of a bacterial strain or species and a composition comprising them provided in a nutritional product or medicament to improve health or prevent or treat a variety of disorders in a subject are also disclosed.
Type:
Application
Filed:
June 26, 2024
Publication date:
October 17, 2024
Inventors:
Michael John Janusz, Anna Malgorzata Plechaty
Abstract: The present invention relates to the association of at least one bacterial strain of the species Enterococcus faecalis and an anti-inflammatory agent, a composition comprising same, and the uses thereof as a medicament, in particular for preventing and/or treating respiratory diseases.
Type:
Application
Filed:
October 13, 2022
Publication date:
October 17, 2024
Inventors:
Muriel THOMAS, Pascale SERROR, Alexandre DAVID-HACHETTE, Jennifer PALOMO
Abstract: The present invention relates to a sprayable formulation comprising live and/or stable bacteria and methods for making such sprayable formulation; in particular in the form of a liquid spray. The invention further relates to the use of this sprayable formulation in human or veterinarian medicine and the use of this sprayable formulation for the prevention and/or treatment of respiratory diseases. The invention further provides methods for the prevention and/or treatment of respiratory diseases.
Type:
Application
Filed:
August 12, 2022
Publication date:
October 17, 2024
Applicants:
Yun NV, Universiteit Antwerpen
Inventors:
Tim Henkens, Ingmar Claes, Alix Simons, Imane Gamgami, Sarah Lebeer, Ilke De Boeck, Irina Spacova
Abstract: The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and/or improving athletic ability.
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
Abstract: Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
Type:
Application
Filed:
January 30, 2024
Publication date:
October 17, 2024
Applicant:
Salk Institute for Biological Studies
Inventors:
Clodagh O'Shea, Shigeki Miyake-Stoner, Colin Powers
Abstract: Use of radix actinidiae chinensis and an extract thereof in preparation of a medicine for treating ulcerative colitis are provided. The radix actinidiae chinensis extract is a radix actinidiae chinensis water extract or a radix actinidiae chinensis alcohol extract. The radix actinidiae chinensis extract has an obvious anti-inflammatory effect on the ulcerative colitis; and because the radix actinidiae chinensis extract has the obvious anti-inflammatory effect on the ulcerative colitis, the radix actinidiae chinensis serving as a raw material also has an obvious anti-inflammatory effect on the ulcerative colitis. Moreover, the radix actinidiae chinensis is widely distributed in China, and is widely cultivated in Shaanxi and other regions. Moreover, the radix actinidiae chinensis is a traditional Chinese medicine for clearing away heat and toxic materials, and its toxic and side effects are small.
Type:
Application
Filed:
January 12, 2024
Publication date:
October 17, 2024
Applicant:
Affiliated Hospital of Guangdong Medical University
Inventors:
Yu ZHOU, Lijiao CUI, Caiyuan YU, Shicai YE
Abstract: A composition for protecting the prostate tissue and inhibiting prostate cancer development has Pumpkin seed extract; Nettle root extract; Berberine; Embilica officinalis (Amla berry); Ganoderma Lucidum (Reishi mushroom); Lycopene; and Selenium.
Abstract: A P2Et treatment using a casein nanoencapsulation method for significantly delaying tumor growth. The nanoencapeulation leads to higher doses of effective P2Et being delivered, improving bioavailability and biological activity and as such, provides a novel perspective on the delivery of these functional ingredients.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising extracts of Isatidis folium and Juglans mandshurica. In addition, the present invention relates to a food composition or an animal feed composition for preventing or alleviating inflammatory bowel disease, both comprising the extracts.
Type:
Application
Filed:
June 26, 2024
Publication date:
October 17, 2024
Inventors:
Mi Won SOHN, Sin Yeon KIM, Jin Gyu CHOI, Se Woong KIM, Dong Hyun KIM
Abstract: A method of topically applying to skin a composition comprising a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus is disclosed.
Type:
Application
Filed:
February 8, 2024
Publication date:
October 17, 2024
Inventors:
Tiffany CARLE, David GAN, Geetha KALAHASTI
Abstract: A composition comprising an aqueous gel with therapeutically effective amounts of glycerin, hesperidin methyl chalcone, and a peptide. The peptide may comprise dipeptide valyl-tryptophane or palmitoyl tripeptide-7, and the addition of a therapeutically effective amount of chlorhexidine gluconate, grapeseed oil, or shea butter may also be used.
Abstract: The present invention relates to a peptide having obesity and muscle loss inhibitory activities, and a use thereof. The peptide has excellent effects on suppressing appetite, promoting energy metabolism, inhibiting fat accumulation, and promoting lipolysis, and inhibits muscle atrophy while promoting muscle synthesis, such that the peptide can be effectively used for the prevention or treatment of obesity and sarcopenia.
Type:
Application
Filed:
June 28, 2022
Publication date:
October 17, 2024
Applicant:
Korea University Research and Business Foundation
Abstract: The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.
Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).
Abstract: The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a disorder associated with misfolded proteins or protein aggregates. In certain instances, the compositions and methods relate to modulators of one or more poly-D/E protein.
Abstract: The invention provides compositions and methods for treating mastitis. Specifically, the invention provides cathelicidin peptides for treating mastitis.
Type:
Application
Filed:
August 5, 2022
Publication date:
October 17, 2024
Inventors:
Hilary Phelps, Brianna Joy Pomeroy Beam, Richard Andrew Ewin, Christopher A. Zook, Michael Kuhn, Xi Zeng
Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.
Type:
Application
Filed:
March 21, 2024
Publication date:
October 17, 2024
Inventors:
Peter Luke Santa Maria, Yunzhi Peter Yang, Sungwoo Kim, Chloe Domville-Lewis
Abstract: Compositions and methods are provided for the treatment of one or both of type 2 diabetes and fatty liver disease, e.g. non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The adipokine Isthmin-1 (ISM1) protein increases adipose glucose uptake while suppressing hepatic lipid synthesis.
Type:
Application
Filed:
July 27, 2022
Publication date:
October 17, 2024
Inventors:
Katrin Jennifer Svensson, Laetitia Voilquin
Abstract: The present invention provides novel and effective cancer immunotherapeutic agents that exhibit therapeutic effects on intractable cancers, particularly cancers for which immune checkpoint inhibitor(s) monotherapy or combined use thereof with other drug(s) is ineffective. Specifically, a cancer therapeutic agent containing an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T cell growth factor (e.g., interleukin-2 (IL-2)) in combination is provided.
Type:
Application
Filed:
August 5, 2022
Publication date:
October 17, 2024
Applicants:
NAGASAKI UNIVERSITY, TOKYO METROPOLITAN HOSPITAL ORGANIZATION
Abstract: The present disclosure provides compositions and methods comprising variant polypeptides of IL-12 with partial agonism relative to wild-type IL-12 for use in therapeutic and non-therapeutic applications.
Abstract: The invention provides compositions and methods for inducing activating a neural receptor. The compositions include a metabolic hormone, which can be used to provide treatment for an addiction or mood disorder in a subject.
Abstract: The present invention includes methods, systems, uses, and means for the delivery of one or more anti-fibrotic agents into the pericardial space for the treatment and prevention of heart failure (HF).
Type:
Application
Filed:
January 12, 2024
Publication date:
October 17, 2024
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
David Schwartzman, Sanjeev G. Shroff, Guy Salama, Charles McTiernan
Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Type:
Application
Filed:
April 19, 2024
Publication date:
October 17, 2024
Applicant:
Xeris Pharmaceuticals, Inc.
Inventors:
Steven PRESTRELSKI, Michael SANDOVAL, Martin DONOVAN
Abstract: A method and compositions of treatment using supplementation, comprising the step of applying a supplement formulation to a human subject via a selected administration route, the supplement formulation comprising therapeutically effective amounts of a hormone supplement, Huperzine A, and a plurality of additional herbal extracts. The hormone supplement may comprise human growth hormone or a precursor or analogue thereof, and the herbal extracts may comprise extracts of Bacopa monnieri or Rhodiola rosea.
Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
Type:
Application
Filed:
March 21, 2024
Publication date:
October 17, 2024
Inventors:
Marshall Grant, Simon R. Bruce, Robert A. Baughman
Abstract: Disclosed herein is an improved process for preparing abaloparatide. The process generally utilizes solid phase peptide synthesis employing an Fmoc-protection scheme. Incorporating a systematic recoupling step of a glutamine residue (Gln16) has been found to minimize the formation of an undesirable des-Gln16 abaloparatide impurity, which is often obtained in significant quantities in the conventional process.
Abstract: The present invention relates to the field of blood products, in particular, to fibrinogen and fibrinogen drug products. The invention provides a fibrinogen drug product in dry, e.g., lyophilized form having a residual moisture content of 2-5% (w/w). The inventors have found that said moisture content is advantageous for viral inactivation by dry heat, which leads to a particularly virus-safe and stable product. The invention further provides a fibrinogen drug product in dry, e.g., lyophilized form, that has an especially low number of subvisible particles (SVPs), and a batch of such drug products. It suitable for reconstitution of 1 g of fibrinogen in water for injection to obtain a fibrinogen solution comprising 6000 or less SVPs having a size of 10-100 ?m and 600 or less SVPs having a size of 25-100 ?m. Methods of preparing the drug products of the invention are also disclosed, as well as these drug products for use in treatment of fibrinogen-deficiency.
Type:
Application
Filed:
August 12, 2022
Publication date:
October 17, 2024
Inventors:
Oliver MANEG, Florian SOCHOR, Wolfgang MÖLLER, Vera OTT, Christoph SCHEICH
Abstract: The present invention refers to a new method for producing a lyophilized pharmaceutical composition comprising human plasma-derived Factor Vlll/Von Willebrand Factor (FVIII/VWF) complex, comprising the steps of: a) providing an initial aqueous solution comprising FVIII/VWF with at least (90) III of FVIII per mg of total proteins, with a ratio of VWF/FVIII activity of at least 0.7; b) adding arginine, histidine, and human serum albumin (HAS); c) lyophilizing the FVIII/VWF solution obtained in step b); and d) reconstituting the lyophilized FVIII/VWF in water for injection thereby obtaining a therapeutic product adequate for the treatment of Hemophilia A and Von Willebrand Disease, wherein prior to administration to a patient, arginine is at a concentration between (42) and (98) mmol/L, histidine is at a concentration between (10) and (24) mmol/L, and albumin is at a concentration between (1) and (2.
Type:
Application
Filed:
August 9, 2022
Publication date:
October 17, 2024
Inventors:
Salvador GRANCHA GAMON, María Mercedes FARO TOMAS, Nuria MARTÍNEZ CREUS
Abstract: Provided herein are methods for treating cancer using an inhibitor of KDSR, a precursor of 3KDS (e.g., palmitate), 3KDS itself, or a combination thereof.
Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Type:
Application
Filed:
October 3, 2023
Publication date:
October 17, 2024
Inventors:
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
Abstract: The claimed invention relates to treatment of virus-related neurological symptoms, particularly methods for treating such symptoms by administering a complement inhibitor. The types of virus-related neurological symptoms that can be treated according to the invention include extreme fatigue, sensory loss such as loss of taste, cognitive changes, seizures, tremor, and stroke, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor.
Type:
Application
Filed:
July 7, 2022
Publication date:
October 17, 2024
Applicant:
Pharming Intellectual Property B.V.
Inventors:
Bruno Giannetti, Anurag Relan, Isaac Melamed
Abstract: The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art.
Abstract: Embodiments provided herein, provide for polypeptides, pharmaceutical compositions, and methods that can be used to target at least two types of cells to modulate the activity of the same to treat disorders, such as autoimmune disorders.
Type:
Application
Filed:
April 17, 2024
Publication date:
October 17, 2024
Inventors:
Alan Crane, John Kulman, Joanne L. Viney
Abstract: The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of peptides having amino acid similarity with IL13RA2, the said antigenic peptide being selected in the group consisting of sequences described in the specification.
Type:
Application
Filed:
June 24, 2024
Publication date:
October 17, 2024
Inventors:
Laurent CHENE, Alban MATHIEU, Matthieu PICHAUD
Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.
Type:
Application
Filed:
May 14, 2024
Publication date:
October 17, 2024
Inventors:
Kayvan Niazi, Raymond Wong, Peter Sieling, Philip T. Liu